Overview

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer

Status:
Recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if pelareorep in combination with different therapies helps to reduce the growth of breast cancer cells and increase the immune system's response to cancer. This study will also help to understand what this treatment does to the tumor. In addition, the safety of the combination treatments with pelareorep will be evaluated.
Phase:
Early Phase 1
Details
Lead Sponsor:
Oncolytics Biotech
Collaborator:
SOLTI Breast Cancer Research Group
Treatments:
Antibodies, Monoclonal
Atezolizumab
Letrozole
Trastuzumab